Under construction – not a live service
Sign in
Not yet taking people in GermanyNo phase

App Tested for Quality of Life and Symptoms in Polycystic Ovary Syndrome

Tests a smartphone app alongside usual care in adults with polycystic ovary syndrome.

Plain-language title generated from the registry record
Registry title: App Impact on Quality of Life and Symptoms in PCOS

Key facts

Where
Chemnitz, GermanySee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 to 65 living in Germany who have a medically confirmed diagnosis of polycystic ovary syndrome (PCOS). It tests whether an app improves quality of life and symptoms over twelve weeks.

Age
18 to 65 years
Sex
Women only
Disease stage
Diagnosed and medically confirmed polycystic ovary syndrome (PCOS), code E28.2
Earlier treatment
No change in hormone therapy, metformin, anti-androgens or psychotropic medicines in the last eight weeks or planned in the next 12 weeks. No earlier or current use of the Endo-App or other digital health apps (DiGAs).

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Current hormonal fertility treatment
  • Current treatment with obesity medicines (for example liraglutide, orlistat)
  • Current psychotherapy
  • Taking part in another clinical study

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT06912594, who can take part

Where in Germany

  • Endo Health GmbHChemnitz, GermanyContact: Teresa Götz, M.Sc.No longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Endo Health GmbH
Trial code
NCT06912594
Record updated
6 April 2025
Original description
This study investigates the influence of a PCOS app on the quality of life and symptoms of individuals with polycystic ovary syndrome (PCOS). The intervention group can use the app over the study period of twelve weeks in addition to care-as-usual (CAU). In the control group, this is compared with no use of the PCOS-App for a twelve-week period, that is, care-as-usual only/ continuation of the current treatment (waitlist design). The aim is to evaluate the effectiveness of the app and to gain insights for the design of future studies. The study is expected to last seven months and include 220 participants.Read full original descriptionShow less

Pilot Study to Investigate the Influence of an App on the Quality of Life and Symptoms of Patients With Polycystic Ovary Syndrome

This study investigates the influence of a PCOS app on the quality of life and symptoms of individuals with polycystic ovary syndrome (PCOS). The intervention group can use the app over the study period of twelve weeks in addition to care-as-usual (CAU). In the control group, this is compared with no use of the PCOS-App for a twelve-week period, that is, care-as-usual only/ continuation of the current treatment (waitlist design). The aim is to evaluate the effectiveness of the app and to gain insights for the design of future studies. The study is expected to last seven months and include 220 participants.

Inclusion: Legal capacity; Resident in Germany; Female gender; Age ≥18 years up to 65 years; Diagnosed and medically confirmed Polycystic Ovary Syndrome (E28.2); Ownership of a smartphone with a compatible iOS or Android version and the ability to operate it; Internet access and an email address for registration, app usage, and completing questionnaires; Willingness to complete questionnaires online; Motivation to use the app regularly; Sufficient knowledge of the German language.

Exclusion: Changes in hormone therapy within eight weeks prior to the start of the study and/or planned within the next 12 weeks; Changes in treatment with metformin within eight weeks prior to the start of the study and/or planned within the next 12 weeks; Current treatment with medications for obesity (e.g., liraglutide, orlistat); Changes in treatment with anti-androgens (e.g., spironolactone, cyproterone acetate, flutamide) within eight weeks prior to the start of the study and/or planned within the next 12 weeks; Changes in treatment with psychotropic medications within eight weeks prior to the start of the study and/or planned within the next 12 weeks; Previous or current access to the Endo-App or other digital health applications (DiGAs); Current nutritional counseling according to §20 SGB V or nutritional therapy according to §43 SGB V, or participation in weight reduction programs; Pregnancy or breastfeeding; Current hormonal fertility treatment; Current psychotherapeutic treatment; Current participation in other clinical studies.

ClinicalTrials.gov NCT06912594